FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models AVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025) Avacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotox ...

NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical- stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2025 financial results and provide a corporate update during a live webcast on Thursday, May 1, 2025, at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast wil ...

Rehovot, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Steakholder Foods Ltd. (NASDAQ:STKH), a leading innovator in 3D-printed meat and fish technology and cultivated cell innovation, today announced its plan to adjust the ratio of the company's American Depositary Shares (ADSs) in relation to its ordinary shares. The adjustment will change the current ratio from one (1) ADS representing one hundred (100) ordinary shares to a new ratio of one (1) ADS representing five hundred (500) ordinary shares, effective ...

Core Viewpoint - Beyond Meat, Inc. is set to report its financial results for the first quarter ending March 29, 2025, on May 7, 2025, after market close, indicating ongoing transparency and engagement with investors [1]. Company Overview - Beyond Meat, Inc. is a leading company in the plant-based meat sector, offering products made from simple ingredients without GMOs, added hormones, antibiotics, and with 0 mg of cholesterol per serving [3]. - The company was founded in 2009 and aims to replicate the taste and texture of animal-based meat while promoting better health for individuals and the planet [3]. - Beyond Meat's brand promise, "Eat What You Love®," reflects its commitment to addressing global issues such as human health, climate change, resource constraints, and animal welfare through a shift to plant-based proteins [3]. Investor Engagement - A conference call will be held on May 7, 2025, at 5:00 p.m. Eastern, 2:00 p.m. Pacific, for investors to discuss the financial results [1]. - A live webcast of the conference call will be available on the company's website, with an option for archiving [2].

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking ...

The Simply Good Foods Company (SMPL) Q2 2025 Earnings Conference Call April 09, 2025 08:30 AM ET Company Participants Conference Call Operator - ModeratorJosh Levine - Vice President of Investor RelationsJeff Tanner - President and CEOSean Mara - CFO Conference Call Participants John Baumgartner - Analyst, Mizuho SecuritiesMegan Clapp - Analyst, Morgan StanleyBrian Holland - Analyst, DA DavidsonMatt Smith - Analyst, StiefelJacob (on behalf of Rob Moscow) - Analyst, TD CowenSteve Flowers - Analyst, Deutsche ...

Dyadic International, Inc. (NASDAQ:DYAI) Q4 2024 Earnings Conference Call March 26, 2025 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President & Chief Executive Officer Joe Hazelton - Chief Operating Officer Conference Call Participants John Vandermosten - Zacks Small Capital Research Vernon Bernardino - HC Wainwright Dick Williams - Williams Resource Group Operator Good evening. And welcome to Dyadic International's year-end 2024 conference call. Currently, all par ...

Call Start: 8:30 January 1, 0000 9:04 AM ET Compugen Ltd. (NASDAQ:CGEN) Q4 2024 - Earnings Conference Call March, 04, 2025, 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leerink Partners Leland Gershell - Oppenheimer Tony Butler - Rodman and Re ...

Company Overview - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system (CNS) disorders [6] - The company utilizes a unique RAP technology platform that targets receptor associated proteins (RAPs) in the brain, aiming to create precision small molecule candidates that address limitations in conventional neurology drug discovery [6] Leadership Appointment - Dr. Jeffrey Sevigny has been appointed as the chief medical officer (CMO) of Rapport Therapeutics, bringing over 15 years of experience in translational and clinical drug development [1][2] - Dr. Sevigny previously served as CMO at Prevail Therapeutics and held senior roles at Eli Lilly, where he contributed to significant corporate successes including financing rounds, an IPO, and an acquisition [2][4] Clinical Strategy and Pipeline - As CMO, Dr. Sevigny will oversee the clinical strategy and advancement of Rapport's pipeline, particularly the RAP-219 program, which is currently in clinical trials for conditions such as focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania [3][6] - The RAP-219 program is noted for its compelling Phase 1 data and aims to achieve neuroanatomical specificity by selectively targeting RAPs expressed in specific brain regions [5][6] Company Vision and Goals - The CEO of Rapport, Abraham N. Ceesay, expressed confidence in Dr. Sevigny's ability to lead the clinical development team and emphasized the importance of collaboration with regulatory authorities and patient advocacy organizations [4] - Dr. Sevigny highlighted the company's strong scientific foundation and the potential of its clinical candidates to provide transformative treatment options for patients with neurological disorders [5]

Kymera Therapeutics (KYMR) Conference February 06, 2025 10:00 AM ET Company Participants Nello Mainolfi - Co-Founder, President, CEO & Director Conference Call Participants Michael Schmidt - Senior Managing Director & Equity Research Analyst - Biotechnology Michael Schmidt Michael Schmidt, senior biotic analyst with Guggenheim, and I'd like to welcome, Nelo Manolfi, the founder, president, and CEO of Chimera to this next fireside chat. Nelo, welcome and thanks for joining us. Nello Mainolfi Thanks, Michael, ...